What does Barbara Deconinck, Endocrinologie-Diabetologie do?

Barbara Deconinck, Endocrinologie-Diabetologie is a specialist medical practice in Langemark-Poelkapelle. Private Limited, started on 24 September 2020, 1 establishment.

What is the address of Barbara Deconinck, Endocrinologie-Diabetologie?

The registered office of Barbara Deconinck, Endocrinologie-Diabetologie is located at Nieuwe Kalsijde 5b, 8920 Langemark-Poelkapelle.

Is Barbara Deconinck, Endocrinologie-Diabetologie still active?

Yes. According to the CBE (31 October 2026) Barbara Deconinck, Endocrinologie-Diabetologie is active, legal situation “Normale toestand”, started on 24 September 2020.

Is Barbara Deconinck, Endocrinologie-Diabetologie registered on Peppol?

Yes, Barbara Deconinck, Endocrinologie-Diabetologie is registered on the Peppol network with ID 0208:0754795008.

What is the enterprise number of Barbara Deconinck, Endocrinologie-Diabetologie?

The enterprise number of Barbara Deconinck, Endocrinologie-Diabetologie is BE0754795008.

Who are the directors of Barbara Deconinck, Endocrinologie-Diabetologie?

According to the 2025 annual accounts, the directors of Barbara Deconinck, Endocrinologie-Diabetologie are: Barbara Deconinck.

Is Barbara Deconinck, Endocrinologie-Diabetologie a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 24 September 2020; 5 annual accounts filed, latest fiscal year 2025; 1 directors known from the annual account.

How much profit did Barbara Deconinck, Endocrinologie-Diabetologie make in 2025?

Barbara Deconinck, Endocrinologie-Diabetologie posted a profit after taxes of € 257,809 in financial year 2025.

What is the revenue of Barbara Deconinck, Endocrinologie-Diabetologie?

As a small company, Barbara Deconinck, Endocrinologie-Diabetologie is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 354,151.

Barbara Deconinck, Endocrinologie-Diabetologie (Private Limited)

Q: When was Barbara Deconinck, Endocrinologie-Diabetologie founded?

Barbara Deconinck, Endocrinologie-Diabetologie was founded on 24 September 2020.

Dossier Barbara Deconinck, Endocrinologie-Diabetologie, printed on 1 November 2026 from databakkes.be/en/0754795008/barbara-deconinck-endocrinologie-diabetologie. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Warning lights

Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.

Tight liquidity NBB

Cash and receivables cover 15 % of short-term debt in 2025; threshold 65 %.

Financials

Financial year 2025

Barbara Deconinck, Endocrinologie-Diabetologie from Langemark-Poelkapelle, company number BE0754795008, closed financial year 2025 with a result of € 257,809 after tax. For that financial year Barbara Deconinck, Endocrinologie-Diabetologie recorded a gross margin of € 354,151 and equity of € 6,000. Compared with financial year 2024, the result moved from € 320,550 to € 257,809. The company is profitable. The buffer shrank hard: equity is 95 % below last year. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on August 31, 2026.

What it is worth Shrank hard

€ 6,000

▼ 95% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Healthy

€ 257,809

▼ 20% vs 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 41,563

▼ 57% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Pays out

€ 378,359 paid out

More than the year’s profit went to the shareholders; reserves fell.

People and assets in 2025

Vehicles and equipment

€ 52,537

▲ € 48,548 vs 2024

Book value of vehicles, furniture and equipment.

Debts at end 2025

Bank debt

None

No bank loans on the last day of the fiscal year.

Owed to suppliers

€ 3,057

▼ 59% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes and wages

€ 13,643

▲ 24% vs 2024

Taxes, VAT and social contributions still to pay.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 381,385 Gross margin 2022: € 381,385 First fiscal year in the series	€ 387,331 Gross margin 2023: € 387,331 ▲ 2% vs 2022 (€ 381,385) Favourable step	€ 424,139 Gross margin 2024: € 424,139 ▲ 10% vs 2023 (€ 387,331) Favourable step	€ 354,151 Gross margin 2025: € 354,151 ▼ 17% vs 2024 (€ 424,139) Unfavourable step	▼ 17%
Profit after taxes	€ 289,876 Profit after taxes 2022: € 289,876 First fiscal year in the series	€ 293,994 Profit after taxes 2023: € 293,994 ▲ 1% vs 2022 (€ 289,876) Favourable step	€ 320,550 Profit after taxes 2024: € 320,550 ▲ 9% vs 2023 (€ 293,994) Favourable step	€ 257,809 Profit after taxes 2025: € 257,809 ▼ 20% vs 2024 (€ 320,550) Unfavourable step	▼ 20%
Equity	€ 807,530 Equity 2022: € 807,530 First fiscal year in the series	€ 99,994 Equity 2023: € 99,994 ▼ 88% vs 2022 (€ 807,530) Unfavourable step	€ 126,550 Equity 2024: € 126,550 ▲ 27% vs 2023 (€ 99,994) Favourable step	€ 6,000 Equity 2025: € 6,000 ▼ 95% vs 2024 (€ 126,550) Unfavourable step	▼ 95%
Total debts	€ 884 Total debts 2022: € 884 First fiscal year in the series	€ 215,232 Total debts 2023: € 215,232 ▲ € 214,347 vs 2022 (€ 884) Unfavourable step	€ 221,646 Total debts 2024: € 221,646 ▲ 3% vs 2023 (€ 215,232) Unfavourable step	€ 281,482 Total debts 2025: € 281,482 ▲ 27% vs 2024 (€ 221,646) Unfavourable step	▲ 27%
Cash	€ 595,968 Cash 2022: € 595,968 First fiscal year in the series	€ 28,102 Cash 2023: € 28,102 ▼ 95% vs 2022 (€ 595,968) Unfavourable step	€ 97,020 Cash 2024: € 97,020 ▲ 245% vs 2023 (€ 28,102) Favourable step	€ 41,563 Cash 2025: € 41,563 ▼ 57% vs 2024 (€ 97,020) Unfavourable step	▼ 57%
Retained profit	€ 801,530 Retained profit 2022: € 801,530 First fiscal year in the series	€ 93,994 Retained profit 2023: € 93,994 ▼ 88% vs 2022 (€ 801,530) Unfavourable step	€ 120,550 Retained profit 2024: € 120,550 ▲ 28% vs 2023 (€ 93,994) Favourable step	€ 0 Retained profit 2025: € 0 ▼ 100% vs 2024 (€ 120,550) Unfavourable step	▼ 100%
Dividend	€ 0 Dividend 2022: € 0 First fiscal year in the series	€ 1,001,530 Dividend 2023: € 1,001,530 Unchanged (€ 0) Unchanged	€ 293,994 Dividend 2024: € 293,994 ▼ 71% vs 2023 (€ 1,001,530) Unchanged	€ 378,359 Dividend 2025: € 378,359 ▲ 29% vs 2024 (€ 293,994) Unchanged	▲ 29%
Bank debt	€ 675 Bank debt 2022: € 675 First fiscal year in the series	€ 0 Bank debt 2023: € 0 ▼ 100% vs 2022 (€ 675) Favourable step	€ 0 Bank debt 2024: € 0 Unchanged (€ 0) Unchanged	€ 0 Bank debt 2025: € 0 Unchanged (€ 0) Unchanged
Balance sheet total	€ 808,414 Balance sheet total 2022: € 808,414 First fiscal year in the series	€ 315,226 Balance sheet total 2023: € 315,226 ▼ 61% vs 2022 (€ 808,414) Unchanged	€ 348,196 Balance sheet total 2024: € 348,196 ▲ 10% vs 2023 (€ 315,226) Unchanged	€ 287,482 Balance sheet total 2025: € 287,482 ▼ 17% vs 2024 (€ 348,196) Unchanged	▼ 17%

Key figures of Barbara Deconinck, Endocrinologie-Diabetologie, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to Barbara Deconinck, Endocrinologie-Diabetologie?

What happened at Barbara Deconinck, Endocrinologie-Diabetologie in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Aug 31, 2026 New annual accounts for financial year 2025: profit of € 257,809 (▼ 20% vs 2024). filed late Source: NBB ↗
Sep 24, 2020 New establishment in Langemark-Poelkapelle. KBO
Sep 24, 2020 Start of the company according to the CBE. KBO
2020 Barbara Deconinck became a director. NBB

In short

From € 289,876 profit in 2022 to € 257,809 profit in 2025.

Paid € 365,500 in corporate taxes since 2022.

Best year ever: 2024, with € 320,550 profit.

Paid out € 1.7 million in dividends to the owners in total.

Original PDFs at the National Bank ↗

Management

Barbara Deconinck

Barbara Deconinck, Endocrinologie-Diabetologie

Behind Barbara Deconinck, Endocrinologie-Diabetologie is Barbara Deconinck.

Directors

According to the 2025 annual accounts

Barbara Deconinck

Director

since 2020

Establishments

Establishment units

Physical locations of this company

Registered office

Nieuwe Kalsijde 5b

8920 Langemark-Poelkapelle

Who else lives here?

A building full of entrepreneurs or one very busy letterbox? Another 1 companies are registered at this address.

All companies at this address →

ERARD VERZEKERINGEN

€ 1.6 million gross margin · 2026

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number

0754.795.008

VAT number

BE 0754.795.008

Registered office

Nieuwe Kalsijde 5b, 8920 Langemark-Poelkapelle

Names & denominations

Barbara Deconinck, Endocrinologie-Diabetologie

Enterprise type

Rechtspersoon

Legal form

Private limited company

Legal situation

Normale toestand

Start date

24 September 2020

Peppol

Active · Active since 22 Dec 2025

Activities · NACE

Activiteiten van medisch specialisten

Overige activiteiten van vrije beroepen en andere wetenschappelijke en technische activiteiten, neg

Overige gespecialiseerde wetenschappelijke en technische activiteiten

View on CBE Public ↗ Annual accounts (NBB) ↗

Barbara Deconinck, Endocrinologie-Diabetologie

Warning lights

Financials

What happened to Barbara Deconinck, Endocrinologie-Diabetologie?

Management

Directors

Establishments

Establishment units

Who else lives here?

Details

Frequently asked questions